BrightSpring Health Services, Inc. Tangible Equity Unit
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTSGU research report →
Price Chart
About the company
BrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance.
- CEO
- Jon Rousseau
- IPO
- 2024
- Employees
- 23,500
- HQ
- Louisville, KY, US
Get TickerSpark's AI analysis on BTSGU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.51B
- P/E
- 39.11
- Fwd P/E
- 107.40
- PEG
- 0.25
- P/S
- 0.84
- P/B
- 6.10
- EV/EBITDA
- 20.34
- Div Yield
- 0.00%
- Gross Margin
- 12.50%
- Op Margin
- 3.61%
- Net Margin
- 2.22%
- ROE
- 16.75%
- ROIC
- 9.83%
Latest fiscal year · YoY change
- Revenue
- $12.91B+14.6%
- Gross Profit
- $1.52B-4.4%
- Op Income
- $295.25M
- Net Income
- $190.67M+1155.6%
- EPS
- $0.94+1104.3%
- OCF Growth
- +1961.8%
- FCF Growth
- +790.7%
- 52W High
- $255.51
- 52W Low
- $111.04
- 50D MA
- $205.00
- 200D MA
- $187.54
- Beta
- 1.71
- RSI (14)
- 44
- Avg Volume
- 14.56K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BrightSpring posted a very strong Q3 with broad-based growth across pharmacy and provider services, raised full-year 2026 guidance, and reaffirmed a positive 2027 growth outlook.· October 30, 2026
- Q3 revenue was $4.2 billion, up 26% year over year, with adjusted EBITDA of $228 million, up 42%, and adjusted EPS of $0.54, up 80%.
- Pharmacy Solutions revenue rose 26% to $3.7 billion and segment EBITDA rose 43% to $202 million; Provider Services revenue rose 31% to $481 million and segment EBITDA rose 30% to $79 million.
- Home and community pharmacy was pressured by the IRA and customer exits, with revenue down 6% year over year, but management said underlying growth improved through the year.
- Cash generation was strong, with $204 million of operating cash flow in the quarter and leverage down to 1.79x at quarter-end.
- Management raised 2026 guidance and said it still expects at least 15% to 20% organic adjusted EBITDA growth in 2027, with quarterly growth rates similar through next year.
For Q3 2026, BrightSpring reported total company revenue of $4.2 billion, up 26% year over year, adjusted EBITDA of $228 million, up 42%, adjusted EPS of $0.54, up 80%, and cash flow from operations of $204 million. Pharmacy Solutions revenue was $3.7 billion, up 26% year over year, with segment EBITDA of $202 million, up 43%; Provider Services revenue was $481 million, up 31%, with segment EBITDA of $79 million, up 30%. Gross profit was $519 million, up 32%. Within Pharmacy Solutions, specialty and infusion revenue was $3.2 billion, up 34%, while Home and Community Pharmacy revenue was $553 million, down 6%; within Provider Services, home health revenue was $288 million, up 50%, rehab care revenue was $82 million, up 8%, and personal care revenue was $111 million, up 8%. For 2026, management now expects total revenue of $15.9 billion to $16.125 billion, adjusted EBITDA of $850 million to $860 million, and operating cash flow of at least $700 million, excluding Community Living; expected 2026 adjusted EBITDA includes about $35 million from the Amedisys/LHC acquisition.
Jon Rousseau framed the quarter as another high-execution period driven by expanded patient reach, operational efficiency, and accretive M&A. He emphasized broad-based growth across pharmacy and provider services, strong demand for lower-cost care settings, and continued investment in technology and AI to improve quality, documentation, hiring, and efficiency. He also highlighted the company’s long-term posture on growth, saying BrightSpring continues to see a durable pipeline of opportunities and remains active in M&A, while reiterating at least 15% to 20% organic adjusted EBITDA growth in 2027.
Jennifer Phipps emphasized the mechanics behind the quarter’s financial outperformance: gross profit rose to $519 million, adjusted EBITDA reached $228 million, and cash flow from operations was $204 million. She noted Pharmacy Solutions segment EBITDA margin was 5.4%, up about 60 basis points year over year, while Provider Services segment EBITDA margin was 16.4%. On the balance sheet, total debt was about $2.2 billion, net debt was $1.5 billion after $718 million of cash, and leverage was 1.79x, including $120 million of share repurchases year to date. She said BrightSpring continues evaluating its capital structure heading into 2027 and expects more of this year’s tech and AI investments to show up in 2027.
Analysts focused heavily on specialty pharmacy script growth, gross profit per script, and whether the pace of LDD-driven growth is sustainable. Management said the 29% specialty script growth was driven mainly by mix, with higher-growth specialty and infusion scripts carrying higher gross profit per script, and stressed that the company focuses on absolute gross profit dollars and EBITDA rather than per-script metrics. Questions also centered on 2027 growth, and management declined to break out LDD versus generic contributions but reiterated that the company has a broad set of growth drivers and expects similar year-over-year EBITDA growth patterns across 2027. On M&A, Rousseau said the pipeline is “as full as ever,” larger deals may become more common than pure tuck-ins, but the company would remain deliberate and would not pursue partnership-style transaction structures.
The call showed strong momentum across nearly every part of the business: pharmacy, provider services, home health, infusion, primary care, and cash flow. Management sounded confident that new branded LDD launches, expanded infusion capabilities, and better home and community pharmacy execution can keep growth elevated, while 2027 was framed as another strong opportunity year.
Home and community pharmacy still faces about $200 million of annual IRA impact in 2026, and management said the business will remain a headwind into next year even as underlying trends improve. A lot of the company’s optimism depends on continued execution in a fragmented but operationally complex set of businesses, plus successful integration of acquired assets and future M&A, all of which management acknowledged require discipline and time.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.6%
- Shares Outstanding
- 198.98M
- Float Shares
- 122.57M
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Union Bancaire Privee, Ubp SA | 8.00M | ▲ 8.00M |
| Voya Investment Management LLC | 1.28M | ▲ 99.58K |
| Blackrock, Inc. | 485.12K | ▼ 7.25K |
| Van Eck Associates Corp | 203.06K | ▲ 2.93K |
| Calamos Advisors LLC | 157.43K | ▼ 144.18K |
| Infrastructure Capital Advisors, LLC | 107.73K | ▲ 107.73K |
| Lord, Abbett & Co. LLC | 97.86K | ▼ 72 |
| Fmr LLC | 86.41K | ▼ 7.99K |
| Point72 Asset Management, L.P. | 51.15K | 0 |
| Ssi Investment Management LLC | 47.53K | ▼ 16.89K |
| Gabelli Funds LLC | 39.60K | 0 |
| Bluecrest Capital Management Ltd | 28.43K | ▼ 73.46K |
Held by 13 ETFs
Biggest fund positions in BTSGU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 26, 26 | Hopper Jeffrey A. | other | 0 |
| Oct 25, 26 | ROUSSEAU JON B | other | 36,355 |
| Sep 14, 26 | Greenwell Scott A. | other | 11,973 |
| Sep 14, 26 | Greenwell Scott A. | sell | 15,099 |
| Sep 14, 26 | Greenwell Scott A. | other | 11,973 |
| Jul 25, 26 | ROUSSEAU JON B | other | 56,319 |
| Jun 20, 26 | Greenwell Scott A. | other | 2,487 |
| Jun 11, 26 | Shah Nigam H. | other | 4,013 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTSGU coverage
Recent articles, reports, and earnings notes.
No research on BTSGU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTSGU report →BrightSpring Health Services, Inc. (NASDAQ:BTSGU) Short Interest Down 77.2% in February
defenseworld.net · Feb 26
BrightSpring Health Services, Inc. $BTSGU Shares Bought by BlueCrest Capital Management Ltd
defenseworld.net · Dec 13
Short Interest in BrightSpring Health Services, Inc. (NASDAQ:BTSGU) Increases By 44.6%
defenseworld.net · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.